Sanofi Stock News

A new vaccine against COVID-19 offers 100% protection against hospitalization, its makers said Wednesday, and they plan to seek regulatory approval.

Sanofi SA (NASDAQ: SNY ) and GlaxoSmithKline plc (NYSE: GSK ) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot. In two separate trials, the companies said their adjuvanted protein-based vaccine demonstrated "universal ability" to boost neutralizing antibodies whether following mRNA or adenovirus shots, as well as 57.9% efficacy against any symptomatic COVID-19 disease. Protection against moderate or severe disease was better at 75%, yet higher … Full story available on Benzinga.com

Drugmakers Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the disease

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Wednesday they will seek regulatory approval for a new COVID-19 vaccine after…

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

Sanofi and GlaxoSmithKline are seeking regulatory approval for their Covid-19 vaccine to be used as a booster, as well as a standalone two-dose shot.

French pharmaceuticals giant Sanofi said Wednesday that its Covid-19 vaccine, developed with Britains GSK, had delivered positive results after nearly a year of delays left it lagging far behind rivals in the race for a jab. The two drugmakers said in a statement they will seek regulatory authoris ..

French multinational healthcare company Sanofi S.A. and British GlaxoSmithKline plc (GSK) shared on Wednesday that they will be seeking "regulatory authorization for [our] COVID-19 vaccine."

Sanofi (SNY) and GlaxoSmithKline (GSK) are planning to seek regulatory authorization for a COVID-19 vaccine.The companies intend to submit data from their booster and phase 3

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend

Sanofi India and Gammon India are the companies that will announce their earnings for quarter ended on December 31, 2021.

Sanofi''s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors Paris, February 22, 2022 . At its meeting on February 22, 2022, Sanofi''s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on May 3, 2022, the renewal of the mandates of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors. Melanie Lee and Carole Piwnica will leave the Board of Directors. The Chairman thanked Carole Piwnica for her contribution to the transformation of the group during her almost 12 years in office, and Melanie Lee for her contribution to the scientific reorientation of the group and the creation of the Scientific Committee. Carole Ferrand is currently Chief Financial Officer of the Capgemini Group and Director of Fnac Darty. She began her career in 1992 at PricewaterhouseCoopers where she worked as an auditor and then a financial advisor.

The Conjugate Vaccine Market research report provides an in-depth overview of the industry including market segmentation by product, technology, vertical and geography. Analysis of the global market with special focus on high growth application in each vertical and fast-growing application

Sanofi found using ticker (SNY) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. With the stocks previous close at 52.87 this would indicate that there is a potential upside of 20.4%. The 50 day moving average now sits at 51.1 and the 200 moving average now moves to 50.97. The company has a market cap of $132,438m. Find out more information at: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $159,391m based on the market concensus. Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.